OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes

Introduction: Increasing insulin prices have led to a renewed debate to determine if Rapid Acting Insulin (RAI) analogs offer an advantage over less expensive Regular Human Insulins (RHI). The steep increase in the cost of RAI has led to rationing of insulin or the total discontinuance of therapy by...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Mora, Pablo, Sutton, David R, Gore, Ashwini, Baliga, Bantwal S, Goldfaden, PharmD, Rebecca, Nikkel, Carla, Sink II, John, Adams-Huet, Beverley
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Diabetes Mellitus and Glucose Metabolism
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208657/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.448
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars